BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

BeOne Medicines Ltd. (NASDAQ:ONC) (formerly BeiGene) on Friday released topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, an investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy.

Mantle cell lymphoma (MCL) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma (NHL)1 that develops in B-cells located in the mantle zone of the lymph nodes.

BeOne plans to present the full data at an upcoming medical meeting.

Also Read: BeOne Cashes In On Amgen’s Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

The BGB-11417-201 Phase 1/2 study enrolled 125 ...